T he effects of percutaneous catheter-based renal denervation (RDN) as new therapy for resistant hypertension have been evaluated several times in the past years. [1] [2] [3] [4] [5] [6] [7] [8] First studies suggested large effects on blood pressure (BP). However, in the first sham-controlled randomized trial, no difference in treated versus controlled participants was found.
T he effects of percutaneous catheter-based renal denervation (RDN) as new therapy for resistant hypertension have been evaluated several times in the past years. [1] [2] [3] [4] [5] [6] [7] [8] First studies suggested large effects on blood pressure (BP). However, in the first sham-controlled randomized trial, no difference in treated versus controlled participants was found. 2 Subgroup analyses of RDN studies have identified different factors of relevance in determining the overall effect of the intervention on BP. [9] [10] [11] Of particular interest is medication adherence. To quantify the effect of the addition of RDN to medical treatment, it is imperative that antihypertensive medical treatment remains unchanged. Recent small studies, using urine or blood samples to detect medication, suggested that adherence is particularly poor in presumed resistant hypertensive participants. [12] [13] [14] The present randomized controlled trial (RCT) was designed to assess the efficacy of RDN in resistant hypertension participants, the primary end point being daytime systolic ambulatory BP (ABPM) at 6 months after RDN. In addition, we explored the effect of adherence on the study outcomes.
Methods

Study Design and Population
The rationale and design of SYMPATHY have been described previously. 15 Briefly, SYMPATHY is a multicenter RCT in 14 centers in the Netherlands. For this trial, a system of conditional reimbursement was available for 4 years (2013-2016), indicating that the intervention was covered by the healthcare insurance, only when patients participated in SYMPATHY. The consequence was that SYMPATHY findings were used by National Health Care Institute to advise the government at the end of 2016 whether RDN should be part of the standard reimbursement package of the Dutch healthcare insurances (https://english.zorginstituutnederland.nl/publications/reports/ 2012/04/06/conditional-reimbursement-of-health-care). Because we had to deliver the report on the SYMPATHY findings to the National Health Care Institute no later than August 1, 2016, participants had to be included before January 1, 2016.
In SYMPATHY adults were included with resistant hypertension, defined as an average daytime systolic ABPM measurement ≥135 mm Hg, despite use ≥3 BP lowering agents or with documented intolerance for ≥2 BP lowering agents. Participating physicians were advised to exclude white coat hypertension, secondary causes of hypertension, and anatomic abnormalities that would make RDN nonfeasible, using a standardized protocol. 16 Randomization was performed in a 2:1 ratio to receive either RDN on top of usual care or usual care alone using a web-based computerized approach, with stratification by hospital and estimated glomerular filtration rate (20- 
Outcome Assessment
The primary outcome was change in daytime systolic ABPM 6 months after RDN or inclusion into the study (control group). Secondary outcomes were change in office systolic BP (SBP), prescribed BP lowering drugs, and change in kidney function. Other outcomes were periprocedural complications. ABPM monitoring was performed noninvasively, with readings every 30 minutes during daytime and every 60 minutes during nighttime and was considered valid when ≥70% of the recordings were successful. Office BP was taken using an automatic device, in sitting position after 10 minutes of rest, twice at both arms using an appropriate cuff size. The mean was used as office BP. Both ABPM and office BP were measured with recommended devices according to the European Society Hypertension/ European Society of Cardiology guidelines. 17 Blood was sampled on the same day as BP was assessed. At study visits, the use of all medication was queried. BP lowering agents were classified according to the Anatomical Therapeutic Chemical classification system of the World Health Organization Collaborating Centre for Drug Statistics. We calculated the defined daily dose of BP lowering agents per participant per visit. The intention was to unchange baseline BP lowering medication till the 6-month visit (primary end point). In case adjustments in medication were necessary, these were made according to a predefined protocol (online-only Data Supplement).
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Important Adjustments During the Course of the Trial
In January 2014, we added participants with documented intolerance to ≥2 BP lowering agents. These participants represent a sizable group of difficult to treat hypertensive patients, for whom RDN could be beneficial as well. Second, from October 2014, National Health Care Institute allowed conditional reimbursement when participants were treated with the EnligHTN Ablation catheter (St Jude Medical, St Paul, MN). 15, 18 Choice of catheter was made by the interventionist. During the course of the trial, it became increasingly clear that the objective assessment of medication adherence is of utmost importance based on reports suggesting poor adherence in this class of participants. [12] [13] [14] We decided to use stored samples for drug level measurements. Of relevance, participants and attending physicians were unaware of the adherence assessments.
The original sample size estimation was set at 300 randomized participants. However, after SYMPLICITY-HTN-3, inclusion slowed dramatically. DENERHTN provided data to assume that a study size of 100 to 150 participants could be sufficient. 1 We estimated that such a number could be feasible by January 1, 2016. We expected a difference of 5 mm Hg in SBP (with SD of 10 mm Hg) between the RDN and control group. Our power would be between 80% and 90% with a 2-side α of 0.05. After consultation with the data safety monitoring board, we decided to continue the study. All described adjustments were approved by the Ethical Committee of University Medical Center Utrecht.
Adherence Measurements
Liquid chromatography combined with tandem mass spectrometry was used to screen BP lowering drugs. This technique has proved to be reliable, accurate, and precise. 19 The acquired mass spectra were compared with an in-house library (compound library and tandem mass spectrometry mass spectral library) built with automated screening software (TOD ID, Thermo Fisher Scientific) which contained the mass/charge of the precursor ion, retention time, product ions, and the entire tandem mass spectrometry spectra of 40 compounds, including metabolites covering over 95% of all BP lowering drugs registered in The Netherlands. Identification was achieved by comparing full tandem mass spectrometry spectra and mass/ charge of precursor ion with the confirmation by the second selected reaction monitoring transitions. Using the developed method, the identification results from spiked serum samples within therapeutic concentration ranges indicated 95% sensitivity and 91% specificity.
Participants were categorized into adherent (81%-100% match prescribed versus measured), poorly adherent (1%-80% match prescribed versus measured), and completely nonadherent (0% match prescribed versus measured).
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Intervention
Usual care was based on the guidelines of the European Society Hypertension/European Society of Cardiology. 17 The RDN procedure was performed by an interventional radiologist or cardiologist.
Data Analyses
Primary efficacy analysis was based on the (modified) intention-totreat population, including all participants randomized with available BP data ≥1 follow-up visit. The primary analysis, that is, mean of change in daytime systolic ABPM between treatment arms was based on t test. All other analyses were performed using either t tests (continuous variables [mean of change]) or χ 2 test for dichotomous variables. Linear regression models were used to study whether treatment effects differed across predefined subgroups, using multiplicative interaction terms (treatment group×subgroup). Linear regression models with adjustments for lifestyle changes and for changes in prescribed and detected medication were run to study the effects of these factors on the observed change in the daytime ABPM and in office systolic pressure. A 2-sided 0.05 level of significance is used. Statistical analyses were done using SPSS version 22 (IBM Corp, Armonk, NY).
Meta-Analysis
To place the SYMPATHY results in perspective of other RDN RCT results, we performed a systematic meta-analysis (online-only Data Supplement).
Results
From May 23, 2013 until January 1, 2016, 139 participants were randomized, 95 to RDN and 44 to usual care. After randomization, 4 participants declined RDN. One participant, randomized to the usual care group, received RDN within the first 6 months. Before the first 6-month visit, 8 participants (5 RDN) withdrew their participation for follow-up measurements ( Figure 1) . Baseline characteristics are shown in 
Effect of RDN on BP
Six-month data on daytime ABPM were available for 124 participants (Figure 1 ). Overall, BP levels declined significantly (Table 2 ). Mean differences between groups in changes in daytime systolic ABPM after 6 months were 2.0 mm Hg (−6.1 to 10.2 mm Hg), in 24-hour systolic ABPM 1.0 mm Hg (−7.1 to 9.1 mm Hg), and in office SBP −8.2 mm Hg (−17.1 to 0.7 mm Hg). The findings were the same when using a complete case analysis approach (Table S1 in the online-only Data Supplement) or sensitivity analysis for patients with true resistant hypertension, defined as the use ≥3 classes of BP lowering drugs (data not shown). Our meta-analysis (including 984 subjects from 7 studies) showed no significant benefit of RDN compared with usual care alone for daytime systolic ABPM (−1.60 mm Hg [−4.32 to 1.11 mm Hg]).
Adverse Events
We observed 17 periprocedural complications, including 4 vascular, 8 bleeding, and 5 other (mild) complications (Table  S2 ). All participants recovered without sequelae. Kidney function declined by 1.5 (−3.1 to 0.1) mL min −1 1.73 m −2 at 6 months, with no difference between groups. During 6-month follow-up, 36 self-reported, unadjudicated serious adverse events were registered: 24 (26%) in the intervention group and 12 (27%) in the usual care group (Table S3) .
Subgroup Analyses
Predefined subgroup analysis showed no statistically significant interaction between kidney function or baseline BP and RDN effects on BP. None of several post hoc subgroup analyses (sex, body mass index, previous cardiovascular history, smoking, urinary sodium excretion, size of the hospital (large centers/small centers), baseline use of spironolactone, and catheter type) reached statistical significance.
Medication Adherence at Baseline and Follow-Up
Prescribed medication did not differ significantly between treatment groups at 6 months and increased in both groups over time (Table 3; Table S4 ). Information on adherence was available for 98 and 83 participants at baseline and at follow-up, respectively (78 pairs). At both study time points, adherence was poor: 80% were either poorly adherent or completely nonadherent. In 54 (29 in RDN group) participants, adherence remained stable. The adherence category changed (eg, from poorly adherent to completely nonadherent) in 31% of the participants (n=24). There was no significant difference in change in adherence between treatment arms (Table 3) .
Medication Adherence and BP
Baseline and 6-month daytime systolic ABPM were the highest in participants completely nonadherent in an analysis restricted to the 78 participants with adherence measurements at baseline and at follow-up (Table S5 ). When medication adherence was the same at baseline and follow-up, daytime systolic ABPM was 3.3 mm Hg (−13.7 to 7.2 mm Hg) lower in favor of the RDN group (Figure 2 (Table S6 ). In particular, no difference was found in factors that potentially drive a larger RDN effect.
Discussion
This is the second largest RCT studying the effect of RDN on BP in participants defined as treatment-resistant hypertensives. Six months after RDN, no significant reduction in daytime or 24-hour systolic ABPM was observed compared with usual care alone.
Effect of RDN on office SBP was of borderline significance. Results are in line with most of the other trials. [1] [2] [3] 5, 6, 8 Our systematic review showed that the pooled effect of RDN on BP is most pronounced for office SBP (−5.4 mm Hg; Figure  S2 ), yet, not statistically significant (P=0.27).
Analyze (n=83)
Excluded from analysis (n=7) 7 patients did not reach the primary outcome for several reasons. The possible reasons of the variability in the effects on BP between participants and between studies have been extensively discussed over recent years.
9,11,21 Relevant factors could be related to the device, the procedure itself, and participant characteristics. In this respect, medication adherence is of particular relevance because recent studies suggested poor adherence in this type of participants. [12] [13] [14] [22] [23] [24] To our knowledge, we are the first trial on RDN to objectively assess medication adherence changes during the study. Strong features of our study are that blood samples were taken on the day of the ABPM and the fact that both participants and treating physicians were unaware of the assessments, resulting in an accurate representation of the every-day reality. Questionnaires used in trials on RDN are likely to overestimate adherence.
1,2,4,6 With a direct adherence assessment, we confirm that BP medication adherence is very low at baseline and at follow-up. This finding is in line with the single direct adherence measurements in the PRAGUE trial (at screening) and DENERHTN trial (at 6-month follow-up). 7, 22 In addition, BP was higher in participants with poor adherence (Table S5) . Therefore, our data support the notion that poor medication adherence contributes to the condition of apparent resistant hypertension.
A second important aspect is that in about one third of the participants adherence to BP lowering drugs either increased or decreased during follow-up. There was a trend toward more detected BP lowering pills at follow-up, more pronounced in the control group than in the RDN group. This may be because of the more intensive follow-up during the trial and the absence of blinding for the intervention (no sham procedure). The large percentage of change, with either decrease or increase in medication use, makes it virtually impossible to quantify the effect of the addition of RDN to medical treatment. This is especially the case when, as in our study, changes occur without the treating physicians knowing it. In those patients with the same number of medication at baseline and at follow-up, all BP measurements suggested a greater, albeit not statistically significant, decrease in the RDN arm. Figure 2 clearly suggests that the overall direction of the effect on BP considerably changed when taking medication adherence into account. In none of the previous RCTs in the RDN field, was adherence quantified in both arms at both baseline and follow-up. It could be that in the other trials, adherence was better than in this study, but it seems appropriate to conclude that poor adherence and changes in adherence were probably major factors of concern.
Our results may have considerable societal impact. These patients use healthcare facilities by (frequently) visiting physicians, by collecting medication from the pharmacy, without using it, meanwhile staying at increased cardiovascular risk. Although the relation between hypertension and increased cardiovascular risk is well established, some participants feel great resistance for prolonged pharmacological therapy. The reasons are likely complex and include the fact that hypertension is usually free of symptoms and that participants experience side effects of medication. This triggers 2 lines of thinking. First, there is great need to more extensively focus on interventions that potentially improve medication adherence. Indeed, in DENERHTN, in which specific efforts were undertaken to improve medication use, full adherence was found in half of the study population, 22 which is much better than the 20% found in this study, but still far from perfect. Alternatively, society could accept that a certain percentage of hypertensive Data are expressed as mean±SD unless stated otherwise. ABPM indicates ambulatory blood pressure measurement; ACE, angiotensin-converting enzyme; BMI, body mass index; BP, blood pressure; CKD-epi, chronic kidney disease epidemiology collaboration equation; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LDL, low density lipoprotein; and SBP, systolic blood pressure.
*Data are expressed as n (%). †Diuretics without spironolactone or other aldosterone antagonists.
participants are not able or willing to use medical treatment for whatever (set of) reason(s). For such participants, alternative approaches, including device-related treatment strategies, could be considered as options worth exploration. An important limitation of our trial is probably that participants were not blinded to the intervention (no sham procedure). We tried to offset this by blinded assessment of the primary outcome, assessment of lifestyle changes that may affect BP for adjustment (salt intake and weight change), and objective measurements of (change in) medication adherence for use in the statistical analyses of the results. Second, although we had a mix of patients (resistant and intolerant), it is unlikely that this affects our findings because our sensitivity analysis revealed no difference in effect when taken the resistant group separately. Another potential limitation might be the use of 2 different devices. This is only an issue when the 2 devices differ in their BP lowering effect, of which no evidence is available, yet. Further, not all patients were on diuretics, which is presently (more or less) accepted as mandatory to meet the definition resistant hypertension. At the time, we designed our study that was not yet so clearly the case. Indeed, it is possible that the lack of diuretic use has influenced our results. Finally, the drug level measurements provided qualitative results: the drug is either detectable or not detectable. Therefore, we might have underestimated the number of changes because dosage and class changes were not detected.
Perspectives
This study shows in primary analysis that RDN is not superior to usual care in reducing BP in participants with resistant hypertension. Medication adherence seems to be very low when participants are unaware of monitoring. Our data suggest that poor adherence (partially) explains the condition of resistant hypertension. Second, and importantly, our data suggest that the direction and the magnitude of the treatment effect considerably change when medication adherence is taken into account. This factor could also have been of relevance in earlier RDN studies. It can only be overcome in future trials by studying unmedicated participants or by detailed monitoring of prescribed and actually used medication. Data are expressed as mean±SD unless stated otherwise. P value presented for the mean difference in effect between the intervention group and control group. ABPM indicates ambulatory blood pressure measurement; BP, blood pressure; CI, confidence interval; DBP, diastolic blood pressure; and SBP, systolic blood pressure. Data are expressed as mean±SD, unless stated otherwise. P value presented for the mean difference between number of prescribed BP lowering drugs and number of measured BP lowering drugs in blood. BP indicates blood pressure.
*Mean change expressed as mean (±SE). †Mean difference between renal denervation and control group for changes 6 mo after renal denervation.
Sources of Funding
SYMPATHY is an investigator-driven trial. Mean difference (±SE) between control group and renal denervation for change in systolic blood pressure (SBP) after 6 mo, presented for intention-totreat population (n=139) and population with stable medication adherence (n=54). ABPM indicates ambulatory blood pressure measurement.
